 | |
| Clinical data | |
|---|---|
| Other names | Levomeloxifene; 6720-CDRI; NNC-460020 |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C30H35NO3 |
| Molar mass | 457.614 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Levormeloxifene (INNTooltip International Nonproprietary Name; developmental code names6720-CDRI,NNC-460020) is aselective estrogen receptor modulator (SERM) which was being developed as an alternative toestrogen replacement therapy for the treatment and prevention ofpostmenopausalbone loss but did not complete development and hence was never marketed.[1] The development was stopped because of a high incidence ofgynecologicalside effects duringclinical trials.[2] Levormeloxifene is thelevorotatoryenantiomer oformeloxifene, which, in contrast, has been marketed, though rather as ahormonal contraceptive.
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
